1/13
06:33 am
nams
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
1/9
08:00 am
nams
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
Medium
Report
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
1/6
07:17 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
1/5
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/16
12:45 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.
12/14
11:36 am
nams
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
12/5
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/2
07:10 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
11/25
08:00 am
nams
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
Medium
Report
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
11/16
10:33 am
nams
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
Low
Report
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
11/7
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6
11:43 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.
11/5
01:31 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $40.00 to $46.00. They now have a "buy" rating on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $40.00 to $46.00. They now have a "buy" rating on the stock.
11/5
08:00 am
nams
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Medium
Report
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
10/30
08:00 am
nams
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
Medium
Report
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
10/21
07:28 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
10/20
07:01 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was given a new $52.00 price target on by analysts at HC Wainwright.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was given a new $52.00 price target on by analysts at HC Wainwright.